Sirtex Medical Reports 13.1 Percent Dose Sales Growth in Fourth Quarter
7/3/2013 7:06:36 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sirtex Medical Limited (ASX:SRX) today announced dose sales of its SIR-Spheres® microspheres targeted radiation therapy for liver cancer grew 13.1 per cent for the quarter ended 30 June 2013 compared to the previous corresponding period. For Financial Year 2013 dose sales of SIR-Spheres microspheres grew 19 per cent. Despite being off a higher base, the FY2013 result delivers continued strong dose sales growth following the 23 per cent growth in FY2012, 19 per cent growth in FY2011 and 14 per cent growth in FY2010.
Help employers find you! Check out all the jobs and post your resume.
comments powered by